About
Lynx Dx develops MyProstateScore 2.0, a diagnostic urine test that assesses the risk of clinically significant prostate cancer by analyzing 18 gene transcripts and optional clinical risk factors to aid physicians in decision-making.
Explore lynxdx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.